Fig. 2
Antitumor efficacy and antigen-specific immune response under SOMV-9RE7 treatment in TC1 tumor-bearing mouse model. A Schematic illustration of experiment schedule. C57BL/6 mice are inoculated with 1 × 105 TC-1 cells subcutaneously (s.c.) on day 0. They are given weekly treatments s.c. of either 10 µg 9RE7, 10 µg SOMV, or SOMV-9RE7 (10 µg SOMV incubated with 10 µg of 9RE7) for 2 weeks. PBMC is collected from the mice 5 days after the final treatment to measure. B Tumor growth curve of TC-1 tumor-bearing mice. C Kaplan–Meier survival curve of TC-1 tumor-bearing mice. D Quantification of E7-specific T cell population. PBMC was collected from each group and processed by staining with PE-conjugated HPV16 E7aa49-57 peptide-loaded H-2Db E7 tetramer and APC-A750-conjugated anti-mouse CD8α antibodies. Representative flow images show gating strategy for identifying CD8+ and PE+ T cells for all 4 groups and E bar graph representation are shown. **p < 0.01, ***p < 0.001, ****p < 0.0001